Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Can...
July 14 2021 - 4:10PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
creating and delivering engineered cells as medicines, today
announced that it has entered into a lease agreement to develop a
163,000 square foot manufacturing facility in Fremont, California.
This facility will support the manufacture of Sana’s late-stage
clinical development and early commercial product candidates across
the multiple technologies in Sana’s pipeline.
“Manufacturing remains a key bottleneck to the development and
broad accessibility of cell- and gene-based medicines. This
facility is a key component in enabling our aspirations to rapidly
innovate, consistently manufacture, and scale production of these
medicines,” said Steve Harr, Sana’s President and CEO. “Sana is
making significant investments to create the scientific insights,
supply chain stability, and operational capabilities to transform
the potentially disruptive scientific insights of the cell and gene
therapy field into important medicines for patients.”
The facility will be designed to provide manufacturing
capabilities across Sana’s portfolio, including allogeneic T cell,
viral vector, and pluripotent stem cell production. The Fremont
location allows close proximity to Sana’s existing technical and
scientific capabilities and access to a strong biotechnology talent
base. As part of the company’s holistic manufacturing strategy,
Sana also intends to work with contract manufacturing partners to
advance its product candidates to the clinic as early as next
year.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are more than 300
people working together to create an enduring company that changes
how the world treats disease. Sana has operations in Seattle,
Cambridge, and South San Francisco. For more information about Sana
Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision, progress, and
business plans; expectations for its development programs, product
candidates and technology platforms, including its pre-clinical,
clinical and regulatory development plans and timing expectations;
its manufacturing plans and strategy; and expectations with respect
to the manufacturing capabilities of the facility. All statements
other than statements of historical facts contained in this press
release, including, among others, statements regarding the
Company’s strategy, expectations, cash runway and future financial
condition, future operations, and prospects, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terminology such as “aim,” “anticipate,” “assume,”
“believe,” “contemplate,” “continue,” “could,” “design,” “due,”
“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. The Company has based
these forward-looking statements largely on its current
expectations, estimates, forecasts and projections about future
events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and
financial needs. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These
statements are subject to risks and uncertainties that could cause
the actual results to vary materially, including, among others, the
risks inherent in drug development such as those associated with
the initiation, cost, timing, progress and results of the Company’s
current and future research and development programs, preclinical
and clinical trials, as well as the economic, market and social
disruptions due to the ongoing COVID-19 public health crisis. For a
detailed discussion of the risk factors that could affect the
Company’s actual results, please refer to the risk factors
identified in the Company’s SEC reports, including but not limited
to its Annual Report on Form 10-K dated March 24, 2021 and
Quarterly Report on Form 10-Q dated May 5, 2021. Except as required
by law, the Company undertakes no obligation to update publicly any
forward-looking statements for any reason.
All product and company names herein may be trademarks of their
registered owners.
Investor Relations:Nicole
Keithinvestor.relations@sana.com
Media:Morgan Warners, Finsbury Glover
Heringmedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jul 2023 to Jul 2024